版本:
中国

BRIEF-Vascular Biogenics study to treat recurrent thyroid cancer met its min goal

Nov 29 Vascular Biogenics Ltd -

* Press release - VBL Therapeutics announces overall survival data for VB-111 monotherapy in phase 2 study for recurrent thyroid cancer

* Study met its primary endpoint, demonstrating disease stabilization and safety, along with a dose-response

* Based on current data, may expand program to additional indications, such as thyroid cancer

* New data show dose-response, evidence overall survival benefit in cohort of patients treated with multiple therapeutic doses of VB-111 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐